Trial · NCT07884903
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Type 2 Diabetes Mellitus | 3 years | 3-year incidence of new-onset type 2 diabetes mellitus diagnosed according to ADA criteria (fasting glucose ≥7.0 mmol/L, HbA1c ≥6.5%, or 2h OGTT ≥11.1 mmol/L) |
| Primary | Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 3 years | 3-year incidence of new-onset MASLD diagnosed by abdominal ultrasound and/or FibroScan with hepatic steatosis, excluding other causes of liver disease |
| Primary | Incidence of Hypertension | 3 years | 3-year incidence of new-onset hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg on at least 2 occasions, or initiation of antihypertensive medication) |
| Primary | Incidence of Atherosclerotic Cardiovascular Disease (ASCVD) | 3 years | 3-year incidence of ASCVD events including coronary heart disease, cerebral infarction, transient ischemic attack (TIA), and peripheral artery disease, confirmed by clinical diagnosis and imaging |
| Secondary | Incidence of Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) | 3 years | Diagnosed by polysomnography with AHI ≥5 events/hour |
| Secondary | Incidence of Polycystic Ovary Syndrome (PCOS) | 3 years | Diagnosed by Rotterdam criteria in women of reproductive age |
| Secondary | Incidence of Osteoarticular Disease | 3 years | New-onset lumbar/knee/hip joint disease confirmed by imaging |
| Secondary | Incidence of Hyperuricemia | 3 years | Serum uric acid \>420 μmol/L (men) or \>360 μmol/L (women) |
| Secondary | Incidence of Dyslipidemia | 3 years | New-onset abnormal lipid profile requiring treatment per guidelines |
| Secondary | Incidence of Microalbuminuria | 3 years | Urine albumin-to-creatinine ratio ≥30 mg/g on 2 occasions |
| Secondary | Progression of Prediabetes to Diabetes | 3 years | Conversion from prediabetes (IFG/IGT) to overt type 2 diabetes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07884903/registered